

EXHIBIT 44

Page 1

Volume II Pages 1-200

Exhibits 26-65

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

IN RE JOHNSON & JOHNSON TALCUM

POWDER PRODUCTS MARKETING,

MDL NO.

SALES PRACTICES, AND PRODUCTS

16-2738 (MAS) (RLS)

LIABILITY LITIGATION

VIDEOCONFERENCE DEPOSITION OF

JOHN GODLESKI, M.D.

Friday, March 29, 2024, 9:15 a.m.

MARRIOTT BOSTON - QUINCY

1000 Marriott Drive

Quincy, Massachusetts 02169

-----REPORTER: Sonya Lopes, RPR, CSR-----

Page 2	Page 4
1 APPEARANCES:	1 I N D E X
2	2
3 Beasley Allen Law Firm	3 EXHIBIT PAGE
4 David P. Dearing, Esq.	4 Exhibit 36, invoice for Converse case.....44
5 218 Commerce Street	5 Exhibit 37, June 22, 2021 letter.....45
6 Montgomery, Alabama 36103-4160	6 Exhibit 38, pathology report, chain of
7 334.269.2343	7 custody document, and
8 david.dearing@beasleyallen.com	8 June 22, 2021 letter.....47
9 for Plaintiffs	9 Exhibit 39, July 27, 2021 letter.....51
10	10 Exhibit 40, pathology report for Converse
11 Shook, Hardy & Bacon LLP	11 case.....52
12 Mark Hegarty, Esq.	12 Exhibit 41, handwritten notes for Converse
13 2555 Grand Boulevard	13 case.....52
14 Kansas City, Missouri 64108-2613	14 Exhibit 42, July 12, 2021 expert report
15 816.474.6550	15 for Converse case.....58
16 mhegarty@shb.com	16 Exhibit 43, Image 20 with corresponding
17 for Defendants	17 spectrum for 41, 42, and 43...96
18	18 Exhibit 44, analysis summary for Rausa
19 Also present: Kerry Stufflebean	19 case.....98
20	20 Exhibit 45, invoice for Rausa case.....101
21	21 Exhibit 46, pathology report for Rausa
22	22 case.....102
23	23 Exhibit 47, second pathology report for
24	24 Rausa case.....103
25	25
Page 3	Page 5
1 I N D E X	1 I N D E X
2	2
3 WITNESS: JOHN GODLESKI, M.D.	3 EXHIBIT PAGE
4	4 Exhibit 48, handwritten notes for Rausa
5 EXAMINATION BY: PAGE	5 case.....104
6 Mr. Hegarty 7, 32, 89, 92	6 Exhibit 49, December 8, 2020 e-mail.....109
7 Mr. Dearing 31, 89, 94, 153	7 Exhibit 50, chain of custody documents
8	8 for Rausa case.....113
9 EXHIBIT PAGE	9 Exhibit 51, chain of custody document....199
10 Exhibit 26, March 29, 2021 e-mail.....7	10 Exhibit 52, March 4, 2021 letter.....121
11 Exhibit 27, March 25, 2021 e-mail.....9	11 Exhibit 53, August 23, 2021 letter.....121
12 Exhibit 28, documents regarding Gallardo	12 Exhibit 54, June 21, 2021 expert report
13 case.....16	13 for Rausa case.....124
14 Exhibit 29, July 27, 2021 letter.....27	14 Exhibit 55, article titled "Migration of
15 Exhibit 30, chain of custody document and	15 talc from the perineum to
16 table.....27	16 multiple pelvic organ
17 Exhibit 31, send-out request form for	17 sites".....143
18 Newsome case.....28	18 Exhibit 56, curriculum vitae.....158
19 Exhibit 32, documents regarding Newsome	19 Exhibit 57, deposition notice.....159
20 case.....28	20 Exhibit 58, plaintiffs' response to
21 Exhibit 33, chain of custody documents	21 deposition notice.....159
22 for Newsome case.....29	22 Exhibit 59, first set of requests for
23 Exhibit 34, printout from IARC Website....29	23 production of documents.....178
24 Exhibit 35, analysis summary for Converse	24
25 case.....36	25

<p style="text-align: right;">Page 6</p> <p style="text-align: center;">I N D E X</p> <p>EXHIBIT PAGE</p> <p>Exhibit 60, response to first set of requests for production of documents.....178</p> <p>Exhibit 61, February 4, 2018 letter.....193</p> <p>Exhibit 62, PowerPoint presentation.....194</p> <p>Exhibits 63-64, consents to release third-party information.....196</p> <p>Exhibit 65, e-mail chain.....196</p> <p>*Exhibits returned to Mr. Hegarty</p>	<p style="text-align: right;">Page 8</p> <p>1 e-mail "Critical blocks to have are E2 and G5." Do</p> <p>2 you recall why you made note of those two blocks as</p> <p>3 being critical?</p> <p>4 A. We almost always do that. We -- what the</p> <p>5 idea is is we're asking here for eight blocks. And</p> <p>6 if the hospital is reluctant to give us the eight</p> <p>7 blocks, we say "These are the most important. Get</p> <p>8 these two at least," is basically what we're saying</p> <p>9 there.</p> <p>10 Q. What was or is your criteria for the</p> <p>11 Judkins case -- and I assume other cases -- for what</p> <p>12 you consider to be, quote, "critical blocks," closed</p> <p>13 quote?</p> <p>14 A. They would be the blocks that have the most</p> <p>15 birefringent particles or the clearest intracellular</p> <p>16 particles. There can be a number of criteria. But</p> <p>17 it's -- if we wanted to look at something in this</p> <p>18 case, it would be these two blocks more than</p> <p>19 anything else because we're -- basically all we're</p> <p>20 saying with that.</p> <p>21 Q. Could you find Exhibit No. 21, which is the</p> <p>22 pathology report for Ms. Judkins? And when you find</p> <p>23 that, identify for me the tissues that correspond to</p> <p>24 blocks E2 and G5.</p> <p>25 A. E2 is a right para-aortic lymph node, and</p>
<p style="text-align: right;">Page 7</p> <p>MR. HEGARTY: Back on the record. We're</p> <p>continuing your deposition from yesterday,</p> <p>Dr. Godleski. Do you understand that you're still</p> <p>under oath?</p> <p>THE WITNESS: Yes.</p> <p>MR. HEGARTY: Thank you.</p> <p style="text-align: center;">EXAMINATION</p> <p>BY MR. HEGARTY:</p> <p>Q. We were -- I want to start by going over</p> <p>some documents that we were provided yesterday and</p> <p>today and then some follow-up questions about what</p> <p>we did yesterday.</p> <p>The first subject I want to talk about is</p> <p>the e-mail we received yesterday where a request was</p> <p>made for the blocks in the Judkins case.</p> <p>MR. HEGARTY: I will mark the e-mail as</p> <p>our next exhibit, which is Exhibit 26.</p> <p>(March 29, 2021 e-mail, Exhibit 26,</p> <p>marked)</p> <p>Q. So I'm showing you, Dr. Godleski,</p> <p>Exhibit 26. Please tell me what that exhibit is.</p> <p>A. This is an e-mail from me to Mr. Dearing</p> <p>and Katie Tucker, who's a legal assistant. And it's</p> <p>a request for blocks on Anne Judkins.</p> <p>Q. Do you see -- you say at the bottom of that</p>	<p style="text-align: right;">Page 9</p> <p>G5 is ovary. And I'm trying to look back to make</p> <p>sure that I have the right -- the correct side. And</p> <p>it's left ovary.</p> <p>Q. Are you able to recall whether the Judkins</p> <p>case you made the request for -- you identified</p> <p>those two as critical blocks because they had the</p> <p>most birefringent or because they were particular</p> <p>tissue that you were interested in or perhaps both?</p> <p>A. Both, probably.</p> <p>Q. Thank you. I'm going to next mark as</p> <p>Exhibit 27 an e-mail we were provided yesterday,</p> <p>which was a block request e-mail for the Tamara</p> <p>Newsome case.</p> <p>(March 25, 2021 e-mail, Exhibit 27,</p> <p>marked)</p> <p>Q. Can you please tell me what Exhibit 27 is,</p> <p>Dr. Godleski?</p> <p>A. This is an -- again, it's a block request.</p> <p>But, also, there was a question posed to us as to</p> <p>whether there was any endometriosis. So we</p> <p>extensively searched. We found this one little area</p> <p>that we described that we didn't feel represented</p> <p>endometriosis but that someone might argue that it</p> <p>did, and we didn't feel that was correct.</p> <p>But we had only this one questionable area</p>

<p style="text-align: right;">Page 142</p> <p>1 Image 14, where is that -- in what tissue is that 2 of? 3 A. That's Block 12B. So that is left external 4 iliac. 5 Q. The image of spectrum -- I'm sorry. The 6 Electron Image 163 is of the left paraaortic lymph 7 node; correct? 8 A. Correct. 9 Q. With regard to the finding of two talc 10 particles in Ms. Rausa's tissue, you did a study 11 where you had a control group of women who indicated 12 they were not talcum powder users. And in two of 13 the six control-group women, you found, based on 14 your recollection, one talc particle in each? 15 A. I believe so. 16 Q. What is that paper? 17 A. That's the McDonald paper, lymph node 18 digestion. 19 MR. HEGARTY: Off the record real quick. 20 (A break was taken) 21 MR. HEGARTY: We're ready to go back on 22 the record after a short break. When we left off, 23 we were talking about the two talc particles that 24 Dr. Godleski had found in Ms. Rausa's case and, in 25 particular, as it relates to a study he had done</p>	<p style="text-align: right;">Page 144</p> <p>1 shows that you found two talc particles in two 2 patients of the six in the group of control 3 patients; correct? 4 A. Yes. 5 Q. And in particular, that's referenced over 6 on page 598 where it says that "Correlative SEM," 7 dash, "EDX of the control tissue blocks showed a 8 total of four talc particles across all patients: 9 Two in Patient 2, right ovary, and two in Patient 3, 10 right fallopian tube." Do you see where I'm 11 reading? 12 A. That's correct. 13 Q. With regard to Ms. Rausa, her talc particle 14 count that you found was the same as you found in 15 two of your six control patients in the paper we 16 marked as Exhibit 55; correct? 17 A. That's correct. 18 Q. So in Ms. Rausa's case, is it your opinion 19 that, based on what you have reviewed, that she's 20 different from what you would see in a control group 21 of women who -- potentially see in a control group 22 of women who never used talcum powder in the 23 perineal area? 24 A. These two women, though, both had pelvic 25 surgery more than 30 years ago so that it's possible</p>
<p style="text-align: right;">Page 143</p> <p>1 where he had a control group of women who reported 2 no talcum powder use in the perineal area. 3 I've handed Dr. Godleski an article -- 4 first author Sandra McDonald -- titled "Migration of 5 talc from the perineum to multiple pelvic organ 6 sites." We'll go ahead and mark it as an exhibit so 7 we can keep a record of it. We'll mark that as 8 Exhibit 55. If you want to hand that back over, 9 Dr. Godleski, we'll put the sticker on there for 10 you. 11 (Article titled "Migration of talc from 12 the perineum to multiple pelvic organ sites," 13 Exhibit 55, marked) 14 Q. So with regard to the paper we've been 15 talking about over the last couple of days as it 16 relates to what you found in a control group of 17 women who didn't report talc use, is Exhibit 55 the 18 paper you've been referencing? 19 A. Yes. 20 Q. Previously, you and I had talked about that 21 paper referencing you finding one talc particle in 22 two different patients. Do you recall us talking 23 about that? 24 A. Yes. 25 Q. The paper we marked as Exhibit No. 5 -- 55</p>	<p style="text-align: right;">Page 145</p> <p>1 that was the source of their talc. 2 Q. You don't list here what type of pelvic 3 surgery; correct? 4 A. No. 5 Q. It's also possible that the pelvic surgery 6 that they had was not the source of the talc you 7 found; correct? 8 A. Possible that it was. 9 Q. And possible that it was not. 10 A. Exactly. 11 Q. Going back to my question, though. Is it 12 still your opinion even or -- let me back up. Let's 13 start again. 14 Let's assume for purposes of my question 15 that the talc particles in these two women in the 16 paper we marked as Exhibit 55 did not -- were not 17 introduced by pelvic surgery. 18 Is it still your opinion that Ms. Rausa -- 19 that four -- what you found in Ms. Rausa can 20 distinguish her based on her talcum powder use from 21 a control group who didn't use talcum powder? 22 A. Yes. 23 Q. Tell me what the basis of that opinion is. 24 A. Ms. Rausa has an exposure history. I don't 25 know what that is, but that will be brought out. At</p>

<p style="text-align: right;">Page 198</p> <p>1 Q. With regard to Exhibit 65 in the -- within 2 the initial e-mail you made reference to, there's a 3 statement that says "If you would be available for 4 phone calls, e-mail, exchanges, or even short-term 5 contracts to help offer scientific opinions on some 6 arguments we have received as we work towards 7 rewriting our screening assessment" or asks that in 8 a question. 9 Was there ever any phone calls or other 10 e-mail exchanges or short-term contracts between you 11 and the folks at Health Canada? 12 A. No. 13 Q. Did the communication with Health Canada 14 end with this e-mail chain? 15 A. Pretty much. 16 Q. Okay. Thank you. Do you have any other 17 documents that concern or relate to your 18 interactions with Health Canada with regard to its 19 risk assessment for talc that we have not marked as 20 exhibits? 21 A. I don't think so. This is it. 22 Q. I believe you already answered this 23 question. Did you ever have any phone calls or 24 other verbal type of communication with anyone at 25 Health Canada regarding their risk assessment?</p>	<p style="text-align: right;">Page 200</p> <p>1 REPORTER'S CERTIFICATE 2 3 I, SONYA LOPES, Registered Professional 4 Reporter and Notary Public in and for the 5 Commonwealth of Massachusetts, certify; 6 That the foregoing proceedings were taken 7 before me at the time and place therein set forth, 8 at which time the witness was properly identified 9 and put under oath by me; 10 That the testimony of the witness, the 11 questions propounded, and all objections and 12 statements made at the time of the examination were 13 recorded stenographically by me and were thereafter 14 transcribed; 15 That the foregoing is a true and correct 16 transcript of my shorthand notes so taken. 17 I further certify that I am not a relative or 18 employee of any attorney of the parties, nor 19 financially interested in the action. 20 I declare under penalty of perjury that the 21 foregoing is true and correct. 22 Dated this 11th day of April, 2024. 23 <%11353,Signature%> 24 Sonya Lopes My Commission Expires: 25 Notary Public October 28, 2027</p>
<p style="text-align: right;">Page 199</p> <p>1 A. Not that I recall. 2 MR. HEGARTY: Let's go ahead and go off 3 the record. Take a quick break. 4 (A break was taken) 5 MR. HEGARTY: It's 4:05. We're back on 6 the record, and I'd indicated to counsel that we 7 still have some additional time to complete for 8 Dr. Godleski's MDL deposition but that I am having a 9 little bit of a challenge with the pain in my wrist 10 from a break I had three weeks ago and would 11 appreciate being able to stop now because I'm having 12 some difficulty in continuing. 13 And I think we're in agreement that we 14 can resume and finish this when we get back together 15 the next time with Dr. Godleski when we're going to 16 talk about the Karl and Badarama (verbatim) cases 17 but finish this separately, then switch to Karl and 18 Badarama. Does that sound acceptable? 19 MR. DEARING: Absolutely. 20 MR. HEGARTY: With that, we will stop 21 the deposition today and pick it up when we get back 22 together. 23 (Chain of custody document, Exhibit 51, 24 marked) 25 (Deposition suspended at 4:05 p.m.)</p>	